Skip to main content

Practice Management

Practice Management
MIPPA: First Broad Changes to Medicare Part D Plan Operations
Jean D. LeMasurier, Babette Edgar, PharmD, MBA
Stakeholder Perspective
Part D under the Medicare Improvements for Patients and Providers Act of 2008
by Mark A. Newsom, MSc
Read More
Practice Management
New Legislations on Generics and Biosimilars Brewing in Congress
Dalia Buffery, MA, ABD
Read More
Practice Management
Paying for Cancer Care: Economic Models Start to Emerge, Dovetailing Healthcare Reform
Caroline Helwick
Read More
Practice Management
Increased Patient Cost-Sharing, Weak US Economy, and Poor Health Habits: Implications for Employers and Insurers
Melinda C. Haren, RN, Kirk McConnell, Arthur F. Shinn, PharmD, FASCP
Stakeholder Perspective
The Cost-Sharing Conundrum: Greater Stakeholder Collaboration Needed
by Paul Anthony Polansky, BSPharm, MBA
Read More
Practice Management
Obesity: Effective Treatment Requires Change in Payers' Perspective
Rhonda Greenapple, MSPH, Jackie Ngai, MS
Stakeholder Perspective
Payers' Incentives Are Not Aligned to Address the Obesity Epidemic
by Jeff Januska, PharmD
Read More
Practice Management
Health Insurance Premium Increases for the 5 Largest School Districts in the United States, 2004-2008
John R. Cantillo, MBA
Stakeholder Perspective
Health Insurance Premium Increases for Large Employers
by F. Randy Vogenberg, PhD, FASHP
Read More
Practice Management
Pay-for-Performance Initiatives: Modest Benefits for Improving Healthcare Quality
Amit Sura, MD, MBA, Nirav R. Shah, MD,MPH
Stakeholder Perspective
The Many Challenges of Pay-for-Performance Programs
by Steven T. Kmucha, MD, JD
Read More
Practice Management
Pharmacogenomics and Drug Development
Michael F. Murphy, MD, PhD
Read More
Practice Management
First Anti-Inflammatory Generic Drug Promising New Therapy for Diabetes
Dalia Buffery, MA, ABD
Read More
Practice Management
Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point?
Rebecca Hyde, Diana Dobrovolny
Stakeholder Perspective
Orphan Drugs: The Potential Impact of Generic Biologics
by Kavita V. Nair, PhD
Read More
Page 30 of 32
Results 291 - 300 of 318